The Race to Develop New Targeted Therapies for Children With Brain Tumors: Where Do We Go?

THERAPEUTIC AREAS OF APPLIED CLINICAL PHARMACOLOGY TRACK

Offers both CME & CPE Credit
UAN #JA4008220-0000-20-015-H01-P
ACPE – 1.5 CONTACT HOURS/KNOWLEDGE-BASED

CO-CHAIRS:
Gilbert J. Burckart, PharmD, Associate Director, Pediatrics, US Food & Drug Administration
Clinton F. Stewart, PharmD, Member & Interim Director, Pharmaceutical Sciences, St Jude Children’s Research Hosp

TARGET AUDIENCE:
This Symposium will be useful for clinicians, regulatory scientists, industry scientists and academic researchers.

GOALS & OBJECTIVES:
Following the completion of this activity, the learner will be able to:
1. Understand the impact of pediatric legislative initiatives on the development of drugs for rare and/or molecularly-diverse tumor types;
2. Understand clinical trial considerations for evaluating targeted therapies for rare and/or molecularly-diverse tumor types;
3. Understand types of pediatric brain tumors and the relevant molecular targets;
4. Describe drug properties and determinants of drug penetration across the blood brain barrier.

Impact of Pediatric Legislative Initiatives: Where We Are & Where We Are Going
Gilbert J. Burckart, PharmD, Associate Director, Pediatrics, US Food & Drug Administration

Pediatric Brain Tumors & Relevant Molecular Markers
Clinton F. Stewart, PharmD, Member & Interim Director, Pharmaceutical Sciences, St Jude Children’s Research Hosp

Evaluating Targeted Therapies in Rare and/or Diverse Tumor Types: Current Status & Promise of Pediatric Master Protocols
Elimika Pfuma Fletcher, PharmD, PhD, Policy Lead/Senior Clinical Pharmacologist, US Food & Drug Administration

Developing a Drug for Brain Tumors: Considerations for Crossing the Blood Brain Barrier
Timothy Heffron, PhD, Associate Director, Genentech Inc

Faculty Panel Discussion, Questions & Answers, Learner Feedback & Evaluation